EVEREST MED (01952) saw its shares rise over 6% in the morning session, reaching a gain of 6.66% at HKD 54.45 as of the latest update, with a trading volume of HKD 142 million. According to EVEREST MED's official WeChat account, the company announced on October 14 that it successfully enrolled the first patient in its global multicenter Phase I clinical trial for the EVM14 injection, a universal cancer therapeutic vaccine, at the NEXT Oncology Virginia clinical research site in the United States. This marks a significant clinical milestone following the approval of the Investigational New Drug (IND) application for EVM14 by both the U.S. Food and Drug Administration (FDA) and the National Medical Products Administration (NMPA) in China. As highlighted in a previous report, the development of EVM14 directly addresses the clinical challenges in treating squamous cell carcinoma. Currently, there is a large patient population suffering from this form of cancer, yet existing standard treatments have not achieved satisfactory results, indicating a substantial unmet medical need. As a universal off-the-shelf vaccine, EVM14 offers advantages such as no HLA screening requirements, ready supply, lower production costs, and applicability across multiple tumor types, showcasing its broad potential in cancer treatment. It is projected that the mRNA cancer vaccine market could reach USD 40.651 billion in a neutral scenario, with universal vaccines expected to have a penetration rate far exceeding that of personalized products due to cost advantages. EVM14's differentiated benefits have enabled it to lead the clinical development process amid intense industry competition.
Comments